Special Issue "Immunogenicities and Immunotherapies in Leukemia"
Deadline for manuscript submissions: 30 April 2024 | Viewed by 78
New advances in immunotherapies have reshaped the cancer treatment landscape. Chimeric antigen receptor (CAR) T-cell therapy has been the best example of demonstrating durable clinical responses in certain types of leukemia. Moreover, various immunotherapies or cellular therapies trials have been established worldwide to assess their clinical efficacy and safety. However, low response rates and consequential off-tumor effects have been documented in several leukemia patients, probably due to the high heterogeneity and low immunogenicity within and between them. New points of view on enhancing leukemic immunogenicity and preventing immune evasion are therefore of clinical importance, not only for immune checkpoint blockage but also for cell-based immunotherapies.
This Special Issue aims to provide a comprehensive overview of the current state of knowledge on immunogenicities and immunotherapies in leukemia. This issue will cover a wide range of topics including the latest advances in immunotherapy for leukemia, the role of immunogenicity in leukemia pathogenesis, and the development of novel immunotherapeutic strategies. The issue will also include reviews of the current literature on immunogenicity and immunotherapy in leukemia, as well as original research articles on these topics. We welcome submissions from researchers working in all areas related to this topic.
Dr. Xufeng Chen
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- cancer immunology
- immune evasion
- cancer immunotherapies
- immune checkpoint blockage
- CAR-T cell therapy
- TCR-T cell therapy